Antibody-drug conjugates versus docetaxel for previously treated advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized controlled trials.

Ther Adv Med Oncol · 2025 · PMC12579195 · PMID 41179119

Europe PMC DOI

hedged sentences

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

narrowly missed statistical significancep = 0.06so close (0.05 < p ≤ 0.1)

When pooled, the overall HR was 0.88 (95% CI: 0.78–1.00), indicating a trend favoring ADCs over chemotherapy, although the result narrowly missed statistical significance ( p = 0.06).

also in 86 other papers

a borderline significant trendno p-value reported

For OS, the pooled HR was 0.88 (95% CI: 0.78–1.00, p = 0.06), reflecting a borderline significant trend favoring ADCs, with negligible heterogeneity ( I 2 = 0%).

also in 52 other papers

a favorable trendno p-value reported

The overall survival, the primary outcome of this meta-analysis, demonstrated a pooled HR of 0.88 (95% CI: 0.78–1.00), suggesting a favorable trend for ADCs over systemic chemotherapy.

also in 559 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.